News
FDA approves Foundayo (orforglipron), the first oral small-molecule GLP-1 medicine for weight management
On 1 April 2026 the FDA approved Foundayo, Eli Lilly's once-daily oral orforglipron, for adults with obesity or with overweight and a weight-related condition. UK and EU status are separate records and are verified independently.
The FDA approved Foundayo (orforglipron) on 1 April 2026 to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related condition, used with a reduced-calorie diet and increased physical activity.
Source: FDA approves first new molecular entity under National Priority Voucher program (1 Apr 2026)
Orforglipron is a small molecule rather than a peptide. It activates the GLP-1 receptor, like semaglutide and liraglutide, but its chemistry is different: GLP-1 activity does not make a medicine a peptide, which matters for how it is made and taken.
Source: FDA approves first new molecular entity under National Priority Voucher program (1 Apr 2026)
The FDA announcement describes it as the first new molecular entity approved under the agency's National Priority Voucher programme.
Source: FDA approves first new molecular entity under National Priority Voucher program (1 Apr 2026)
Why it matters
A once-daily tablet that does not need refrigeration or injection changes the practicalities of GLP-1 treatment. In the UK, Foundayo is already sold by online clinics; GLPInfo's price comparison covers it. The US approval establishes US status only.
What remains uncertain
- UK and EU regulatory status are separate records; GLPInfo publishes them only from the MHRA and EMA records.
- Long-term comparative data against injectable GLP-1 medicines are still accumulating.
On the timeline
About this article. Written by the GLPInfo editorial team with AI assistance from the official sources linked on the page, and approved by the site owner before publication. It has not yet been reviewed by a named clinician. Published 13 Sep 2026. Information, not medical advice: decisions about any medicine sit with you and a qualified prescriber. Spotted an error? Report a correction.